Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
B Liu, M Li, Z Zhou, X Guan, Y Xiang - Journal of autoimmunity, 2020 - Elsevier
The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global
pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are …
pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are …
COVID-19: Immunology and treatment options
S Felsenstein, JA Herbert, PS McNamara… - Clinical …, 2020 - Elsevier
The novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions. As
protective immunity does not exist in humans and the virus is capable of escaping innate …
protective immunity does not exist in humans and the virus is capable of escaping innate …
Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province
K Liu, YY Fang, Y Deng, W Liu, MF Wang… - Chinese medical …, 2020 - mednexus.org
Background: The 2019 novel coronavirus (2019-nCoV) causing an outbreak of pneumonia
in Wuhan, Hubei province of China was isolated in January 2020. This study aims to …
in Wuhan, Hubei province of China was isolated in January 2020. This study aims to …
Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study
Y Deng, W Liu, K Liu, YY Fang, J Shang… - Chinese medical …, 2020 - mednexus.org
Background: The 2019 novel coronavirus has caused the outbreak of the acute respiratory
disease in Wuhan, Hubei Province of China since December 2019. This study was …
disease in Wuhan, Hubei Province of China since December 2019. This study was …
Severe acute respiratory syndrome: historical, epidemiologic, and clinical features
Over the past 2 decades 2 previously unknown coronaviruses (CoVs), the severe acute
respiratory syndrome CoV (SARS-CoV) and the Middle East respiratory syndrome CoV …
respiratory syndrome CoV (SARS-CoV) and the Middle East respiratory syndrome CoV …
Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study
P Zhang, J Li, H Liu, N Han, J Ju, Y Kou, L Chen… - Bone research, 2020 - nature.com
The most severe sequelae after rehabilitation from SARS are femoral head necrosis and
pulmonary fibrosis. We performed a 15-year follow-up on the lung and bone conditions of …
pulmonary fibrosis. We performed a 15-year follow-up on the lung and bone conditions of …
Laboratory testing of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2 (2019‐nCoV): Current status, challenges, and countermeasures
Y Yan, L Chang, L Wang - Reviews in medical virology, 2020 - Wiley Online Library
Emerging and reemerging infectious diseases are global public concerns. With the outbreak
of unknown pneumonia in Wuhan, China in December 2019, a new coronavirus, SARS …
of unknown pneumonia in Wuhan, China in December 2019, a new coronavirus, SARS …
Recent discovery and development of inhibitors targeting coronaviruses
T Pillaiyar, S Meenakshisundaram, M Manickam - Drug discovery today, 2020 - Elsevier
Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded
RNA genome. Currently, six human CoVs have been reported including human coronavirus …
RNA genome. Currently, six human CoVs have been reported including human coronavirus …
Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective
AK Singh, S Majumdar, R Singh, A Misra - Diabetes & Metabolic Syndrome …, 2020 - Elsevier
Background and aims Interest in corticosteroid therapy in COVID-19 has been rekindled
after the results from Randomized Evaluation of COVid-19 thERapY (RECOVERY) Trial …
after the results from Randomized Evaluation of COVid-19 thERapY (RECOVERY) Trial …
Coronaviruses—drug discovery and therapeutic options
In humans, infections with the human coronavirus (HCoV) strains HCoV-229E, HCoV-OC43,
HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract …
HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract …